Obese study: MB-1
Official title A Clinical Trial to Investigate the Safety and Efficacy of MB-1 on Metabolic Health in Overweight and Obese Adults
ClinicalTrials.gov ID: NCT07363148
What this study is testing
- What it's testing
- The study wants to find out whether MB‑1 changes body weight after 84 days compared to a placebo. It also looks at other health measures like blood pressure, heart rate, and body composition.
- Who it's for
- Adults who are overweight or obese and want to try a new weight‑loss treatment.
- What's involved
- Participants will receive either MB‑1 or a placebo and will have their weight, blood pressure, heart rate, and body composition measured. They will also fill out appetite and satiety questionnaires and get a DEXA scan.
- Time commitment
- The study lasts 84 days and includes several visits for measurements and questionnaires during that period.
You might receive a placebo (an inactive treatment) instead of the study drug.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 50
You may be able to join if
- Males \& females aged 18-50 years, inclusive
- BMI of 25.0 to ≤ 34.9 kg/m²
- Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable...
- Double-barrier method
- Intrauterine devices
You likely can't join if
- Individuals who are pregnant, breast feeding, or planning to become pregnant during the study
- Allergy, sensitivity, or intolerance preventing consumption of the investigational product or placebo ingredients
- Gastric bypass surgery or other surgeries to induce weight loss
- Metal implants or other physical characteristics/limitations that may affect DEXA scan results as assessed by the QI
- Currently taking weight loss medications or participated in a weight loss program within the past three months as assessed by the QI
- Current or history of eating disorders as assessed by the QI
See the full eligibility criteria
Who can join
- Males \& females aged 18-50 years, inclusive
- BMI of 25.0 to ≤ 34.9 kg/m²
- Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant...
- Double-barrier method
- Intrauterine devices
- Non-heterosexual lifestyle and agrees to use contraception if planning on changing to heterosexual partner(s)
- Vasectomy of partner at least 6 months prior to screening
- Abstinence and agrees to use contraception if planning on becoming sexually active during the study
- Stable body weight defined as a \<5% change in body weight in the three months prior to baseline as assessed by the QI
- Abdominal obesity: Waist circumference of \> 94 cm (37 inches) in men and \> 80 cm (31.5 inches) in women
- Willingness to complete questionnaires, records and diaries associated with the study and to complete all clinic visits
- Agrees to maintain current lifestyle habits (diet, medications, supplements, and sleep) as much as possible throughout the study
- Provided voluntary, written, informed consent to participate in the study
- Healthy as determined by medical history as assessed by Qualified Investigator (QI)
What rules you out
- Individuals who are pregnant, breast feeding, or planning to become pregnant during the study
- Allergy, sensitivity, or intolerance preventing consumption of the investigational product or placebo ingredients
- Gastric bypass surgery or other surgeries to induce weight loss
- Metal implants or other physical characteristics/limitations that may affect DEXA scan results as assessed by the QI
- Currently taking weight loss medications or participated in a weight loss program within the past three months as assessed by the QI
- Current or history of eating disorders as assessed by the QI
- Unstable metabolic disease or chronic diseases as assessed by the QI
- Current or history of any significant diseases of the gastrointestinal tract as assessed by the QI
- Unstable hypertension. Treatment on a stable dose of medication for at least 3 months will be considered by the QI
- Participants residing in the same household as another study participant unless they are enrolled consecutively (e.g. not actively enrolled at the same time)
- Type I or Type II diabetes
- Significant cardiovascular event in the past 6 months. Participants with no significant cardiovascular event on stable medication may be included after assessment by the QI on a case-by-case basis
- History of or current diagnosis with kidney and/or liver diseases as assessed by the QI on a case-by-case basis, with the exception of history of kidney stones in participants who are symptom free for 6 months
- Self-reported confirmation of current or pre-existing thyroid condition. Treatment on a stable dose of medication for at least 3 months will be considered by the QI
- Self reported confirmation of glaucoma
- Major surgery in the past 3 months or individuals who have planned surgery during the course of the study. Participants with minor surgery will be considered on a case-by-case basis by the QI
- Cancer, except skin basal cell carcinoma completely excised with no chemotherapy or radiation with a follow up that is negative.
- Individuals with an autoimmune disease or are immune compromised as assessed by the QI
- Self-reported confirmation of a HIV-, Hepatitis B- and/or C-positive diagnosis as assessed by the QI
- Self-reported confirmation of blood/bleeding disorders as assessed by the QI
- Chronic use of cannabinoid products (\>2 times/week) as assessed by the QI. Occasional users will be required to washout and abstain for the duration of the study period
- Regular use of tobacco or nicotine products in the past six months, as assessed by the QI. Occasional users will be required to washout and abstain for the duration of the study period
- Alcohol intake average of \>2 standard drinks per day as assessed by the QI
- Alcohol or drug abuse within the last 12 months
- Current use of prescribed and/or over-the-counter (OTC) medications, supplements, and/or consumption of food/drinks that may impact the how well it works and/or safety of the investigational product (Section 7.3)
- Blood donation 30 days prior to baseline, during the study, or a planned donation within 30 days of the last study visit
- Participation in other clinical research studies 30 days prior to baseline, as assessed by the QI
- Individuals who are unable to give informed consent
- Any other condition or lifestyle factor, that, in the opinion of the QI, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant
The study team makes the final eligibility decision.
Where it is enrolling
- London, Ontario, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 50 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at London, Ontario, Canada. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.